Good News | Hinova Pharmaceuticals Reaches Overseas Licensing Agreement with Evommune for VAV1 Molecular Glue Degrader
Highlights
Hinova Pharmaceuticals has entered into an exclusive license agreement with Evommune. Hinova will receive an upfront payment totaling US$30 million and is entitled to potential development, regulatory and commercialization milestone payments of up to approximately US$1.07 billion, as well as tiered royalties.
HP570, independently developed by Hinova, is a highly potent and highly selective oral VAV1 molecular glue degrader with best-in-class potential, intended for the treatment of multiple autoimmune diseases.
The Investigational New Drug (IND) application for HP570 has been approved by the U.S. FDA; the IND in China remains under review, and a Phase I clinical trial is expected to commence shortly.
Overseas Exclusive Licensing Collaboration
November 5, 2026 — Chengdu, China; New York, U.S.; Palo Alto, California, U.S. — Hinova Pharmaceuticals Co., Ltd. (SSE: 688302) and Evommune, Inc. (NYSE: EVMN), a U.S. biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases, jointly announced today that they have entered into an exclusive license agreement for HP570, an efficient and highly selective oral VAV1 molecular glue degrader with best-in-class potential, independently developed by Hinova using its targeted protein degradation technology platform.
Under the agreement, Hinova grants Evommune exclusive rights to develop, manufacture and commercialize HP570 worldwide outside the Greater China region (including Mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan).
Evommune will pay Hinova an upfront payment totaling US$30 million. Hinova is also entitled to potential development, regulatory approval and commercialization milestone payments of up to approximately US$1.07 billion, as well as tiered royalties based on net sales of the product in the licensed territory. In addition, under certain circumstances specified in the agreement, Hinova will be entitled to additional sublicensing income sharing. BFC Group served as the exclusive financial advisor to Hinova for this transaction, and Fangda Partners served as the exclusive legal counsel.
Mechanism of Action and Preclinical Data of HP570
VAV1 is an important signaling protein involved in T-cell and B-cell activation, predominantly expressed in immune cells. HP570 induces degradation of the VAV1 protein through a molecular glue mechanism, thereby modulating aberrant immune activity associated with autoimmune diseases. Compared with JAK family proteins, which are widely expressed across multiple tissues, the expression profile of VAV1 provides a mechanistic basis for potential differences in safety and tolerability; the related clinical benefits remain to be confirmed in clinical trials. In preclinical studies, HP570 demonstrated pharmacological activity in multiple animal models of immune-mediated diseases and showed higher potency than other investigational VAV1 degraders in human immune cell experiments. The planned Phase I clinical trial will evaluate its safety and pharmacokinetic profile.
About the Collaboration
Dr. Chen Yuanwei, Founder and Chairman of Hinova Pharmaceuticals, stated: “We are pleased to reach this collaboration with Evommune. The development progress of HP570 reflects the innovative capabilities of Hinova’s targeted protein degradation and translational medicine platforms, and represents an important step in bringing our independently developed achievements to the global stage. Evommune brings extensive drug development experience and an international footprint in chronic inflammatory diseases, and we look forward to leveraging our respective strengths to accelerate the development of this VAV1 degrader with best-in-class potential, providing new treatment options for more patients.”
Dr. Jeegar Patel, Chief Scientific Officer of Evommune, stated: “VAV1 is a highly promising therapeutic target in immunology, with the potential to maintain robust immunomodulatory activity while improving upon the safety and tolerability challenges faced by some existing treatment options. HP570 features a differentiated molecular scaffold and has undergone structure-based optimization, demonstrating sub-nanomolar potency, high selectivity, and the potential to support once-daily oral dosing in preclinical studies. We look forward to its Phase I clinical results and plan to advance a Phase II clinical trial in rheumatoid arthritis in 2027, further exploring its therapeutic potential in T-cell and B-cell-driven autoimmune diseases.”
Mr. Greg Moss, Chief Business and Legal Officer of Evommune, stated: “The in-licensing of HP570 (EVO570) is an important step in expanding Evommune’s immunology pipeline and will further strengthen our portfolio in T-cell and B-cell-driven autoimmune diseases. We are impressed by Hinova’s capabilities in innovative drug discovery and development advancement. Through this collaboration, we look forward to combining our respective strengths to advance this candidate with broad application potential, creating long-term value for patients and shareholders.”
About VAV1 and HP570
VAV1 is a guanine nucleotide exchange factor (GEF) predominantly expressed in immune cells. It participates in T-cell receptor and B-cell receptor signaling, regulating immune cell activation, cytokine production and migration. HP570 is an investigational oral VAV1 molecular glue degrader that promotes VAV1 degradation by recruiting intracellular protein degradation machinery.
About Hinova Pharmaceuticals
Headquartered in Chengdu, China, Hinova Pharmaceuticals is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines, with a strategic focus on oncology, autoimmune diseases and metabolic diseases. The company has one approved prostate cancer treatment in China and has established a development pipeline covering small-molecule drugs, deuterated drugs, PROTAC degraders and molecular glue degraders, aiming to address significant unmet clinical needs.
About Evommune
Evommune is a biopharmaceutical company listed on the New York Stock Exchange (ticker: EVMN), headquartered in Palo Alto, California, U.S. Evommune focuses on developing innovative therapies for chronic inflammatory diseases, seeking to reduce the long-term health impact of persistent inflammation and improve patients’ quality of life by advancing a differentiated pipeline.
Disclaimer:
1. This article is intended to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not for advertising purposes. Hinova Pharmaceuticals does not make any recommendation, commitment or guarantee regarding any drug or indication.
2. If any content in this article concerns information on products not yet marketed, such products are at the research, development or clinical trial stage and are subject to uncertainty; the final outcome shall be subject to the approval of the National Medical Products Administration.
3. Risk warning: Any forward-looking statements in this article concerning judgments about the external environment, the company’s development strategy or future plans do not constitute a substantive commitment by the company to investors. Investors are advised to invest rationally and to pay attention to investment risks.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D


